2024 European Society of Cardiology Guidelines
New ESC guidelines recommend renal denervation. Class IIb.1
The future of hypertension care is now
ESC guidelines recommend RDN for uncontrolled hypertension patients.
Elevate hypertension care options as you know them. ESC recommends RDN as an evidence-based complementary hypertension treatment option for your patients.1
- In patients with uncontrolled and resistant hypertension
- Treated with 3 or fewer antihypertensive drugs, including diuretic
Symplicity™ blood pressure procedure
> 9 mmHg
in OSBP in patients off
and on medications2,3
With over 25,000 real-world RDN patients and counting, Medtronic Symplicity™ blood pressure procedure has delivered clinically significant and sustained BP reductions in multiple clinical trials.2–7
A third pillar of hypertension care.
Lifestyle
modification
Medication
management
Renal
denervation
*Indicates a required field
Your information is being collected by Medtronic Australasia Pty Ltd and/or Medtronic New Zealand Limited and dealt with in accordance with our Privacy Policy which can be found at www.medtronic.com.au. We may share your information with our employees, third-party suppliers and agents working on our behalf, including overseas companies within the Medtronic Group most likely Singapore, Netherlands, Philippines and the United States. We take all reasonable steps to ensure that any recipient is bound by similar privacy protections to those in ANZ. While Medtronic cannot guarantee against any loss, misuse or alteration to data, we take reasonable steps to prevent such occurrences. You may request access to, and correction of, your personal information by sending and email to rs.datasubjectrightrequest@medtronic.com, or complain about a breach of your privacy by sending an e-mail to privacy@medtronic.com.
Selecting "no" to marketing emails above will not affect your other email selections, and a Medtronic representative will still reach out via email, if selected. Your personal data will be used to manage your relationship with Medtronic, and, if you consent, to provide you with relevant email updates based on your user preferences. You can opt-out of receiving such emails at any time by clicking the unsubscribe link in the relevant email. Medtronic may use pixels and other technologies in emails to gather statistics around email opening and click reporting for us to improve our communications and to provide you with relevant content. For more information see the Medtronic privacy site.
1. McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO). European Heart Journal. 2024;00: 1–107. https://doi.org/10.1093/eurheartj/ehae178
2. Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444–1451. doi: 10.1016/S0140-6736(20)30554-7.
3. Kandzari DE, Townsend RR, Kario K, et al. Safety and efficacy of renal denervation in patients taking antihypertensive medications. J Am Coll Cardiol. 2023;82(19):1809–1823. doi: 10.1016/j.jacc.2023.08.045.
4. Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet. 2022;399(10333):1401–1410. doi: 10.1016/S0140-6736(22)00455-X.
5. Mahfoud F. The evidence: efficacy, durability, and safety of RF renal denervation. Presented at EuroPCR 2023, Paris, France.
6. Mahfoud F, Mancia G, Schmieder RE, et al. Outcomes following radiofrequency renal denervation according to antihypertensive medications: Subgroup analysis of the Global SYMPLICITY Registry DEFINE. Hypertension. 2023;80(8):1759–1770. doi: 10.1161/HYPERTENSIONAHA.123.21283.
7. Medtronic data on file. RDN Catheter Historical Data, June 2023. Data includes both Symplicity Flex and Symplicity Spyral.
Disclaimer: This page may include information about products that may not be available in your region or country. Please consult the approved indications for use. Content on specific Medtronic products is not intended for users in markets that do not have authorisation for use.